WS #10441
AbbVie agrees to acquire Apogee Therapeutics for ~$10.9B, adding late-stage immunology programs.
AbbVie Acquires Apogee Therapeutics
AbbVie agrees to acquire Apogee Therapeutics for ~$10.9B, adding late-stage immunology programs.
AbbVie agrees to acquire Apogee Therapeutics for ~$10.9B, adding late-stage immunology programs.
AbbVie agrees to acquire Apogee Therapeutics for ~$10.9B, adding late-stage immunology programs.